RecruitingPhase 3

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

Côte d’Ivoire, Ethiopia8,000 participantsStarted 2023-05-08

Plain-language summary

A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age ≥ 18 years
✓. Documented HIV infection
✓. CD4 count criteria:
✓. Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment

✕. Contraindications to azithromycin:
✕. Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)
✕. Off-label azithromycin prophylaxis or requirement for prolonged (\> 7 days) azithromycin (or macrolide) therapy

All-cause mortality

Timeframe: 24 weeks after randomization

NCT IDNCT05580666

SponsorPopulation Health Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-11-30

REVIVE Study Coordinator